Oxurion Receives Transparency Update from Atlas Special Opportunities LLC

Oxurion NV, a biopharmaceutical player based in Leuven, Belgium, has informed of the receipt of an adjusted transparency notification in accordance with Belgian law. This notification, dated January 13, 2025, comes from Atlas Special Opportunities LLC. It reveals that as of January 30, 2024, Atlas held 35,039 shares out of a total of 3,192,223 outstanding shares of Oxurion, thus falling below the 3% threshold through the sale of voting securities.

This press release corrects the one published on January 3, 2025. Oxurion continues to focus on the development of novel ophthalmic therapies for retinal diseases. For more information, visit the company's website.